As the number of recoveries goes up, demand for oxygen, ventilators falls

ICMR is also likely to delete the use of plasma therapy for Covid-19 treatment from the national guidelines

Hospital, Coronavirus
Breathing tubes hang next to a Covid-19 patient on a ventilator
Ruchika Chitravanshi New Delhi
3 min read Last Updated : Oct 20 2020 | 11:30 PM IST
India has recorded the highest number of recovered Covid-19 patients in the world at 6.7 million. With this, the number of Covid patients requiring ventilators, ICU and oxygen support has also been steadily declining.

Meanwhile, the Indian Council of Medical Research (ICMR) is likely to issue an advisory based on the interim findings of the solidarity trial that showed that drugs such as Remdesivir and Hydroxychloroquine are not very effective in treating the disease.

“The study is yet to be peer reviewed, but debates and discussions are going on. These drugs are not performing as expected. We will take into cognizance the results of these trials and issue an advisory,” said Balram Bhargava, director general, ICMR.

The World Health Organisation’s solidarity trial had enrolled almost 12,000 patients in 500 hospital sites in over 30 countries including India.

The study has found that Remdesivir, Hydroxychloroquine, Lopinavir/Ritonavir and Interferon had little or no effect on overall mortality, initiation of ventilation and duration of hospital stay in hospitalised patients.

ICMR is also likely to delete the use of plasma therapy for Covid-19 treatment from the national guidelines, Bhargava said. This is based on the findings of the study on plasma therapy that showed that it did not benefit mortality or reduce the chances of a patient’s condition going from moderate to severe.


India has seen a drop in the number of patients requiring oxygen. The need for ventilator or ICU support has also been on a steady decline since late September. The maximum number of patients requiring these facilities crossed 75,000 on September 25. The number fell to around 57,000 on October 19.

The trend echoes the latest findings of the government panel – that India had passed the Covid peak in September. The total number of new cases have also declined from the peak level of over 97,000 in mid-September to less than 47,000 on October 20.

ICMR is also studying re-infection in patients who developed Covid symptoms 90 days after getting cured. “Usually, the antibodies can last from three to five months. A person can get re-infected once the antibodies reduce. That's why it is important to continue taking precautions even after one has recovered,” Bhargava said.

Vaccination roadmap

The government is, meanwhile, holding discussions on the logistics of vaccinating people. The health ministry said there were 28,000 cold storages with temperature trackers for vaccines in India, which send information in real time to the central server.

Speaking on the health ID under the National Digital Health Mission (NDHM), Rajesh Bhushan, secretary, health ministry, said that it was not a mandatory requirement and no one would be deprived of vaccination for not having a health ID. “There are multiple IDs that can be utilised just like in the election scenario.”

He also said that the NDHM’s data management policy would be revised on the basis of over 7,000 comments that the government had received. India, he added, had surplus capacity for vials and syringes domestically and the health ministry had its own inventory, too, which would be utilised along with the industry’s.
 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusICMROxygen

Next Story